Three Seasons Wealth’s Regeneron Pharmaceuticals REGN Stock Holding History

Three Seasons Wealth’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.53M	Buy	+2,021	New	+$1.53M	0.14%	63

Other funds holding REGN

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $127B AUM 33.25% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Three Seasons Wealth's REGN Position: Q3 2026 in Review

Three Seasons Wealth opened a new position in Regeneron Pharmaceuticals (REGN) in Q3 2026: 2,021 shares worth $1.53M. The stake represents 0.14% of the portfolio and ranks #63 among its holdings.

895 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

Three Seasons Wealth held 2,021 shares of Regeneron Pharmaceuticals worth $1.53M as of Q3 2026.
Regeneron Pharmaceuticals was a new Three Seasons Wealth position in Q3 2026.
Regeneron Pharmaceuticals made up 0.14% of Three Seasons Wealth's portfolio in Q3 2026, its #63 holding.
895 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on Three Seasons Wealth's 13F filing for Q3 2026, filed 3 Nov 2026.